Effects of angiotensin receptor blockade on atrial electrical remodelling and the ‘second factor’ in a goat burst-paced model of atrial fibrillation

Abstract

Atrial fibrillation (AF) is self-perpetuating, via mechanisms of acute electrical remodelling and ‘second factors’ acting over a longer time course. Renin—angiotensin system (RAS) blockade may inhibit AF self-perpetuation. We evaluated the effects of RAS blockade with candesartan in a burst-paced goat model of lone AF in which both mechanisms are known to operate. Bioactivity of oral candesartan was demonstrated in 10 goats by inhibition of the pressor effect of angiotensin II. The effects of candesartan on electrical remodelling were assessed in 12 placebo and 12 candesartan-treated goats in a 28-day burst pacing protocol. To assess the effects of candesartan on second factors (structural remodelling), 16 goats underwent further 28-day periods of burst pacing (two periods in 16 goats, three periods in eight goats) each separated by periods of sinus rhythm sufficient for electrical remodelling to reverse. There was a progressive rise in angiotensin levels in both groups. Candesartan (0.5 mg/kg/day) achieved a 76% blunting of the pressor effect of angiotensin II and had no effect on electrical remodelling; the half time for fall of atrial effective refractory period (AERP) was 22.3 ± 4.9 h (placebo) and 22.0 ± 3.2 h (candesartan) (p = ns). Candesartan had no effect on AF stability, which progressively increased over successive 28-day periods (ANOVA p < 0.05). Candesartan had no effect on atrial electrical remodelling or the operation of ‘second factors’ in a goat model of lone AF. These findings suggest that any benefits of RAS blockade in patients with AF are unlikely to be due to direct effects on atrial remodelling.

Keywords

angiotensin animal model atrial fibrillation atrial remodelling candesartan electrophysiology

Get full access to this article

View all access options for this article.

References

Feinberg WM , Blackshear JL , Laupacis A. , Kronmal R. , and Hart RG Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Int Med 1995 ; 155: 469-73.

Stewart S. , McMurray JJ Atrial fibrillation and the aging population- an emerging epidemic. Eur Heart J 2002; 23: 617. 3. Kannel WB , Wolf PA , and Benjamin EJ Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am J Cardiol 1998; 82: 2N-9N.

Wijffels MC , Kirchhof CJ , Dorland R. , and Allessie MA Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-8.

Allessie M. , Ausma J. , Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation . Cardiovasc Res 2002; 54: 230-46.

Todd DM , Fynn SP , Walden AP , Hobbs WJ , Arya S. , and Garratt CJ Repetitive 4-week periods of atrial electrical remodeling promote stability of atrial fibrillation: time course of a second factor involved in the self-perpetuation of atrial fibrillation. Circulation 2004; 109: 1434-9.

Madrid AH , Bueno MG , Rebollo JM , et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.

Berk BC Angiotensin II receptors and angiotensin IIstimulated signal transduction . Heart Fail Rev 1998; 3: 87-99.

Brundel BJ , Ausma J. , van Gelder IC , et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002; 54: 380-9.

Kumagai K. , Nakashima H. , Urata H. , Gondo N. , Arakawa K. , and Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.

10.

Schoonderwoerd BA , Ausma J. , Crijns HJ , Van Veldhuisen DJ , Blaauw EH , and Van Gelder IC Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol 2004; 15: 1167-74.

11.

Ausma J. , Wijffels M. , Thone F. , Wouters L. , Allessie M. , and Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96: 3157-63.

12.

Thompson PJ , Kemp MW , McAllister WA , Al Habet SM , and Turner-Warwick ME Angiotensin-converting enzyme. Investigation of diurnal variation, the effect of a large dose of prednisolone, and prednisolone pharmacokinetics in patients with sarcoidosis . Am Rev Respir Dis 1986; 134: 1075-7.

13.

Kerber RE , Wilson RL , and Marcus ML An animal model for experimental echocardiographic studies. J Clin Ultrasound 1976; 4: 343-7.

14.

Sanmillan, Cabrera A , and Santos-Gallego G. Enalapril prevents electrical and structural remodeling in a canine model of atrial fibrillation: molecular mechanisms. Heart Rhythm 2005; 2: S70.

15.

Shi Y. , Li D. , Tardif JC , and Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002 ; 54: 456-61.

16.

Shinagawa K. , Mitamura H. , Ogawa S. , and Nattel S. Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002; 54: 438-46.

17.

Nakashima H. , Kumagai K. , Urata H. , Gondo N. , Ideishi M. , and Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-7.

18.

Anné W. , Willems R. , Holemans P. , et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007; 43: 148-58.

19.

Pedersen OD , Bagger H. , Kober L. , and Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-80.

20.

Madrid AH , Marín IM , Cervantes CE , et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5: 114-20.

21.

Vermes E. , Tardif JC , Bourassa MG , et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight into the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.

22.

The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. New Engl J Med 2009; 360: 1606-17.

23.

Frustaci A. , Chimenti C. , Bellocci F. , Morgante E. , Russo MA , and Maseri A. : Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.